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OBJECTIVES: To utilize WebTV technology to assess the
effect of coexistence of depressive symptomatology on 
the health status of arthritic individuals, in a nationally
representative elderly sample. METHODS: Depression 
in arthritic individuals was measured using the Center 
for Epidemiological Studies Depression scale (CESD-20).
Health related quality of life (HRQOL) was assessed
using Short Form 36 (SF-36) scale. Random Digit Dialing
(RDD) survey procedures were used to recruit individu-
als having different types of arthritis, but having no pre-
viously diagnosed depression (N = 550), drawn from US
households across 44 states. Each participating house-
hold was outﬁtted with a free WebTV and Internet con-
nection. Cut-off score of ≥16 was used on the CESD-20
scale to identify arthritic persons at risk for clinical
depression. CESD-20 and dimension scores such as Neg-
ative Affect (NA), Positive Affect (PA), Somatic Symp-
toms (SS), Interpersonal Problems (IP), Mental Health
(MH), Physical and Mental component Summary scores
(PCS and MCS) were computed. Conceptually relevant
associations between CESD-20 and SF-36 subscales were
determined. RESULTS: A response rate of 87% (N = 480)
was achieved following the administration of surveys in
August 2001. Using CESD scores, 16% (n = 76) of the
respondents were found to be at risk for clinical depres-
sion. Signiﬁcant negative correlations between SS and
PCS scores (r = -0.416, P = 0.000), and between CESD
and MH scores (r = -0.68, P = 0.000) were found. No
signiﬁcant differences on the CESD, SS, PCS, MCS scores
were found across different arthritic types, races, and
gender. However, differences on all these measures were
signiﬁcant (P < 0.05) for the elderly categorized into dif-
ferent subgroups based on age. CONCLUSION: Con-
current administration of SF-36 and CESD-20 in patients
with a chronic disease is recommended for the measure-
ment of depressive symptomatology and health status.
Preliminary examination of associations among crucial
study variables suggests that CESD somatic items may
actually somewhat elevate the depression symptom scores
in arthritis.
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OBJECTIVES: The aim of this study was to determine
utility values for different health outcomes associated
with the use of non-steroidal anti-inﬂammatory drugs
(NSAIDs) or paracetamol in the treatment of osteoarthri-
tis. METHODS: Six physicians and 73 nurses responded
to a postal survey based on the EQ-5D. Health care pro-
fessionals were considered an appropriate survey group
because they have a good understanding of how the alter-
native health state scenarios would impact on patients.
Five health states were deﬁned based on published clini-
cal trial data and expert opinion: 1) osteoarthritis patients
managed with an NSAID who are free of gastrointestinal
complications; 2) osteoarthritis patients managed with 
an NSAID who have minor NSAID-type gastrointestinal
complications (e.g., dyspepsia, reﬂux); 3) osteoarthritis
patients managed with an NSAID who have an uncom-
plicated perforation, ulcer or bleed (PUB); 4) osteo-
arthritis patients managed with an NSAID who have a
complicated PUB; and 5) osteoarthritis patients managed
with paracetamol. Utility values were derived for each of
the ﬁve health states based on the responses to the survey
and the EQ-5D scoring algorithm. RESULTS: Patients
without gastrointestinal side effects had the highest utility
value (mean utility value: 0.667). Patients with compli-
cated PUBs had the lowest utility (-0.151), while higher
utilities were seen in patients with uncomplicated PUBs
(0.456) and those with minor NSAID-type gastrointesti-
nal complications (0.557). Patients whose osteoarthritis
was managed with paracetamol had lower utility than
those patients managed with traditional NSAIDs who are
free of gastrointestinal complications—a result consistent
with the relative efﬁcacy of NSAIDs and paracetamol in
the treatment of osteoarthritis. CONCLUSIONS: Thera-
pies with lower rates of gastrointestinal-related toxicity
can improve the quality of life of osteoarthritis sufferers.
Our study enables new osteoarthritis treatments which
offer lower rates of GI toxicity than traditional NSAIDs
to be evaluated in a cost-utility framework.
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OBJECTIVES: Biochemical failure after deﬁnitive treat-
ment for prostate cancer is common. We determined
second treatment patterns in biochemical failure patients
initially managed with radical prostatectomy (RP) and
radiation (XRT). METHODS: Three hundred eighty-one
and 259 patients managed with RP and XRT, respectively,
who failed biochemically were identiﬁed from CaPSURE,
a national prostate cancer registry. Failure was a PSA >
0.4 after RP and three consecutive rises in PSA above the
nadir for XRT. Logistic regression was used to determine
predictors of second treatment after failure. RESULTS:
Median time to failure was 20.8 and 25.3 months for RP
and XRT. One point twenty-one (32%) and 75 (29%) of
RP and XRT failure patients received second treatment.
Median time between failure and second treatment was
8.2 and 17.6 months for RP and XRT. Second treatments
following RP were hormonal therapy (59%) and XRT
(41%) and for XRT were mainly hormonal therapy
